Protease, Microenvironment and Cancer : E. Liaudet-Coopman


Darlix A, Hirtz C, Thezenas S, Maceski A, Gabelle A, Lopez-Crapez E, Firmin N, Guiu S, Jacot W, Lehmann S The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases. BMC Cancer. 2019;19(1):110. doi:10.1186/s12885-019-5287-z

Chartron E, Theillet C, Guiu S, Jacot W Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data. Crit. Rev. Oncol. Hematol.. 2019;133. doi:10.1016/j.critrevonc.2018.10.012

Larbouret C, Poul M-A, Chardès T Mimicking polyclonal immune response in therapy: from combination of two monoclonal antibodies to oligoclonal antibody-based mixtures. 2019;in press.

Ashraf Y, Mansouri H, Laurent-Matha V, Alcaraz L, Roger P, Guiu S, Derocq D, Robin G, Michaud H-A, Jarlier M, Pugnière M, Robert B, Puel A, Martin L, Landomiel F, Bourquard T, Achour O, Fruitier-Arnaudin I, Pichard A, Deshayes E, Turtoi A, Poupon A, Boissière-Michot F, Pirot N, Bernex F, Jacot W, du Manoir S, Theillet C, Pouget J-P, Navarro-Teulon I, Bonnefoy N, Pèlegrin A, Chardès T, Martineau P, Liaudet-Coopman E Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. J Immunother Cancer. 2019;7(1):29. doi:10.1186/s40425-019-0498-z

Bourillon L, Bourgier C, Gaborit N, Garambois V, Llès E, Zampieri A, Ogier C, Jarlier M, Radosevic-Robin N, Orsetti B, Delpech H, Theillet C, Colombo P-E, Azria D, Pèlegrin A, Larbouret C, Chardès T An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. Int. J. Cancer. Mar 18, 2019. doi:10.1002/ijc.32273

Neiveyans M, Melhem R, Arnoult C, Bourquard T, Jarlier M, Busson M, Laroche A, Cerutti M, Pugnière M, Ternant D, Gaborit N, Chardès T, Poupon A, Gouilleux-Gruart V, Poul M-A A recycling anti-transferrin receptor-1 monoclonal antibody as an efficient therapy for erythroleukemia through target up-regulation and antibody-dependent cytotoxic effector functions. MAbs. 2019;11(3):593-605. doi:10.1080/19420862.2018.1564510

Didier R, Mallavialle A, Ben Jouira R, Domdom M, Tichet M, Auberger P, Luciano F, Tartare-Deckert S, Deckert M Targeting the Proteasome-Associated Deubiquitinating Enzyme USP14 Impairs Melanoma Cell Survival and Overcomes Resistance to MAPK-Targeting Therapies. Mol. Cancer Ther.. 2018;17(7):1416-1429. doi:10.1158/1535-7163.MCT-17-0919

Ogier C, Colombo P-E, Bousquet C, Canterel-Thouennon L, Sicard P, Garambois V, Thomas G, Gaborit N, Jarlier M, Pirot N, Pugnière M, Vie N, Gongora C, Martineau P, Robert B, Pèlegrin A, Chardès T, Larbouret C Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer. Cancer Lett.. 2018;432. doi:10.1016/j.canlet.2018.06.023

Guiu S, Mollevi C, Charon-Barra C, Boissière F, Crapez E, Chartron E, Lamy P-J, Gutowski M, Bourgier C, Romieu G, Simony-Lafontaine J, Jacot W Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers. Br. J. Cancer. 2018;119(1):76-79. doi:10.1038/s41416-018-0142-6

Ploquin A, Pistilli B, Tresch E, Frenel J, Lerebours F, Lesur A, Loustalot C, Bachelot T, Provansal M, Ferrero J, Coussy F, Debled M, Kerbrat P, Vinceneux A, Allouache D, Morvan F, Dalenc F, Guiu S, Rouzier R, Vanlemmens L 5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study. Eur. J. Cancer. 2018;95. doi:10.1016/j.ejca.2018.02.030

Estupina P, Fontayne A, Barret J-M, Kersual N, Dubreuil O, Le Blay M, Pichard A, Jarlier M, Pugnière M, Chauvin M, Chardès T, Pouget J-P, Deshayes E, Rossignol A, Abache T, de Romeuf C, Terrier A, Verhaeghe L, Gaucher C, Prost J-F, Pèlegrin A, Navarro-Teulon I The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells. Oncotarget. 2017;8(23):37061-37079. doi:10.18632/oncotarget.15715

Viala M, Alexandre M, Thezenas S, Lamy P-J, Maran-Gonzalez A, Gutowski M, Colombo P-E, Romieu G, Jacot W Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2- pN0 early breast cancers. Breast Cancer Res. Treat.. 2017;165(3):611-621. doi:10.1007/s10549-017-4373-7

Jankowski C, Guiu S, Cortet M, Charon-Barra C, Desmoulins I, Lorgis V, Arnould L, Fumoleau P, Coudert B, Rouzier R, Coutant C, Reyal F Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis. Breast Cancer Res. Treat.. 2017;161(1):73-81. doi:10.1007/s10549-016-4040-4

Le Clorennec C, Bazin H, Dubreuil O, Larbouret C, Ogier C, Lazrek Y, Garambois V, Poul M-A, Mondon P, Barret J-M, Mathis G, Prost J-F, Pèlegrin A, Chardès T Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3. Mol. Cancer Ther.. 2017;16(7):1312-1323. doi:10.1158/1535-7163.MCT-16-0886

Del Rio M, Mollevi C, Bibeau F, Vie N, Selves J, Emile J-F, Roger P, Gongora C, Robert J, Tubiana-Mathieu N, Ychou M, Martineau P Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies. Eur. J. Cancer. 2017;76. doi:10.1016/j.ejca.2017.02.003

Chuvin N, Vincent D, Pommier R, Alcaraz L, Gout J, Caligaris C, Yacoub K, Cardot V, Roger E, Kaniewski B, Martel S, Cintas C, Goddard-Léon S, Colombe A, Valantin J, Gadot N, Servoz E, Morton J, Goddard I, Couvelard A, Rebours V, Guillermet J, Sansom O, Treilleux I, Valcourt U, Sentis S, Dubus P, Bartholin L Acinar-to-Ductal Metaplasia Induced by Transforming Growth Factor Beta Facilitates KRASG12D-driven Pancreatic Tumorigenesis. Cell Mol Gastroenterol Hepatol. 2017;4(2):263-282. doi:10.1016/j.jcmgh.2017.05.005

Le Clorennec C, Lazrek Y, Dubreuil O, Larbouret C, Poul M-A, Mondon P, Melino G, Pèlegrin A, Chardès T The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation. Oncotarget. 2016;7(24):37013-37029. doi:10.18632/oncotarget.9455

Régent A, Ly K, Lofek S, Clary G, Tamby M, Tamas N, Federici C, Broussard C, Chafey P, Liaudet-Coopman E, Humbert M, Perros F, Mouthon L Proteomic analysis of vascular smooth muscle cells in physiological condition and in pulmonary arterial hypertension: Toward contractile versus synthetic phenotypes. Proteomics. 2016;16(20):2637-2649. doi:10.1002/pmic.201500006

Lefebvre C, Bachelot T, Filleron T, Pedrero M, Campone M, Soria J-C, Massard C, Arnedos M, Lacroix-Triki M, Garrabey J, Boursin Y, Deloger M, Fu Y, Commo F, Scott V, Lacroix L, Dieci M, Kamal M, Ferrerro J-M, Romieu G, Vanlemmens L, Mouret Reynier M-A, Théry J-C, Le Du F, Guiu S, Dalenc F, Clapisson G, Bonnefoi H, Jimenez M, Le Tourneau C, André F Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis. PLoS Med.. 2016;13(12):e1002201. doi:10.1371/journal.pmed.1002201

Paillas S, Ladjohounlou R, Lozza C, Pichard A, Boudousq V, Jarlier M, Sevestre S, Le Blay M, Deshayes E, Sosabowski J, Chardès T, Navarro-Teulon I, Mairs R, Pouget J-P Localized Irradiation of Cell Membrane by Auger Electrons Is Cytotoxic Through Oxidative Stress-Mediated Nontargeted Effects. Antioxid. Redox Signal.. 2016;25(8):467-484. doi:10.1089/ars.2015.6309

Jacot W, Pons E, Frenel J-S, Guiu S, Levy C, Heudel P, Bachelot T, D'Hondt V, Darlix A, Firmin N, Romieu G, Thezenas S, Dalenc F Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. Breast Cancer Res. Treat.. 2016;157(2):307-318. doi:10.1007/s10549-016-3828-6

Mahiddine K, Mallavialle A, Bziouech H, Larbret F, Bernard A, Bernard G CD99 isoforms regulate CD1a expression in human monocyte-derived DCs through ATF-2/CREB-1 phosphorylation. Eur. J. Immunol.. 2016;46(6):1460-1471. doi:10.1002/eji.201546143

Hamouda M-A, Jacquel A, Robert G, Puissant A, Richez V, Cassel R, Fenouille N, Roulland S, Gilleron J, Griessinger E, Dubois A, Bailly-Maitre B, Goncalves D, Mallavialle A, Colosetti P, Marchetti S, Amiot M, Gomez-Bougie P, Rochet N, Deckert M, Avet-Loiseau H, Hofman P, Karsenti J-M, Jeandel P-Y, Blin-Wakkach C, Nadel B, Cluzeau T, Anderson K, Fuzibet J-G, Auberger P BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice. J. Exp. Med.. 2016;213(9):1705-1722. doi:10.1084/jem.20150983

Maria A, Toupet K, Bony C, Pirot N, Vozenin M-C, Petit B, Roger P, Batteux F, Le Quellec A, Jorgensen C, Noël D, Guilpain P Antifibrotic, Antioxidant, and Immunomodulatory Effects of Mesenchymal Stem Cells in HOCl-Induced Systemic Sclerosis. 2016;68(4):1013-1025. doi:10.1002/art.39477

Valcourt U, Carthy J, Okita Y, Alcaraz L, Kato M, Thuault S, Bartholin L, Moustakas A Analysis of Epithelial-Mesenchymal Transition Induced by Transforming Growth Factor ?. Methods Mol. Biol.. 2016;1344. doi:10.1007/978-1-4939-2966-5_9

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés